ライフサイエンスコーパス: fatty acid-binding protein

1 nine, aspartate transaminase, and heart-type fatty acid binding protein).

2 ro-brain natriuretic peptide, and heart-type fatty acid binding protein).

3 ts confirm the function of this protein as a fatty acid binding protein.

4 sis, but this was not seen in the absence of fatty acid binding protein.

5 gh recently it was proposed to function as a fatty acid binding protein.

6 raction, we coexpressed S100A7 and epidermal fatty acid binding protein.

7 tubulin beta 2 A, histone H2B and brain type fatty acid binding protein.

8 ntration and its correlation with intestinal fatty acid-binding protein.

9 aperone proteins, regulatory proteins, and a fatty acid-binding protein.

10 4) (Ki = 33 (+/-2) nM) bound to keratinocyte fatty acid-binding protein.

11 xpress the differentiation marker intestinal fatty acid-binding protein.

12 pocalin, kidney injury molecule 1, and liver fatty acid-binding protein.

13 ugs, including icosapent ethyl and adipocyte fatty-acid-binding protein.

14 ies and a structural motif characteristic of fatty acid binding proteins.

15 functions are redundant with those of other fatty acid-binding proteins.

16 the same critical functions in all bacterial fatty acid-binding proteins.

17 he mean methylation of 1444 genes, including fatty acid binding protein 1 (FABP1), fatty acid binding

18 In cells expressing human fatty acid-binding protein 1 (FABP1), GW7647 treatment i

19 es [ Acot1 (Acyl-CoA thioesterase 1), Fabp1 (fatty acid-binding protein 1), and Ehhadh (enoyl-coenzym

20 ein 1 (1.35), C-C motif chemokine 20 (1.35), fatty acid-binding protein (1.33), tumor necrosis factor

21 Fatty acid binding protein-1 (FABP-1), which is protecti

22 , cystatin-C, beta2-microglobulin, and liver fatty acid binding protein-1) to healthy volunteer level

23 mational fluctuations of unfolded intestinal fatty acid binding protein (131 aa, 15 kDa) by using flu

24 luding fatty acid binding protein 1 (FABP1), fatty acid binding protein 2 (FABP2), melanocortin 2 rec

25 or-1 being increased, no change to adipocyte fatty acid binding protein 2 and suppression of CD36.

26 unctional missense mutation [Ala54Thr of the fatty acid-binding protein 2 gene (FABP2)] has previousl

27 R-1 were used to demonstrate that heart-type fatty acid-binding protein-3 (FABP3) is a target of miR-

28 Fatty acid binding protein 4 (FABP4 or aP2) is an intrac

29 the functional properties of the cytoplasmic fatty acid binding protein 4 (FABP4) has advanced with t

30 pt levels of PPARG and the PPARG target gene fatty acid binding protein 4 (FABP4) in pbASCs.

31 Fatty acid binding protein 4 (FABP4) is a fatty acid cha

32 Fatty acid binding protein 4 (FABP4) is a leaderless lip

33 Fatty acid binding protein 4 (FABP4) plays an important

34 Fatty acid binding protein 4 (FABP4), an intracellular l

35 The fatty acid binding protein 4 (FABP4), commonly known as

36 Fatty acid binding protein 4 (FABP4, also known as aP2)

37 t and rapid suppression of the expression of fatty acid binding protein 4 and peroxisome proliferator

38 f bone sialoprotein, lipoprotein lipase, and fatty acid binding protein 4 are the preferred markers f

39 s of reduced lipolysis and lower circulating fatty acid binding protein 4 levels.

40 d expression of UCP1 when expressed from the fatty acid binding protein 4 promoter, even when mice ar

41 pose Grp78-knockout mouse utilizing the aP2 (fatty acid binding protein 4) promoter-driven Cre-recomb

42 ne-sensitive lipase, lipoprotein lipase, and fatty acid binding protein 4) versus sham.

43 A expression of the differentiation markers; fatty acid binding protein 4, peroxisome proliferator-ac

44 receptor cysteine rich type 1 protein M130, Fatty acid binding protein 4, Plasminogen activator inhi

45 upporting genes (e.g., SP7 [osterix], FABP4 [fatty acid binding protein 4], ANGPT1 [angiopoietin 1],

46 Fatty acid-binding protein 4 (FABP4 or aP2 in mice) has

47 Fatty acid-binding protein 4 (FABP4) delivers ligands fr

48 Fatty acid-binding protein 4 (FABP4) is an adipogenic pr

49 and expression of C/EBPalpha, PPARgamma and fatty acid-binding protein 4 (FABP4).

50 diminishing binding to its downstream target fatty acid-binding protein 4 (FABP4).

51 A protein array identified upregulation of fatty acid-binding protein 4 (FABP4, also known as aP2)

52 dipogenesis, and also its downstream target, fatty acid-binding protein 4 (FABP4/aP2).

53 Fenugreek decreased hepatic expression of fatty acid-binding protein 4 and increased subcutaneous

54 a, CCAAT/enhancer-binding protein alpha, and fatty acid-binding protein 4 expression in mouse embryon

55 tagonist [IL-1ra], hepatocyte growth factor, fatty acid-binding protein 4, and tissue plasminogen act

56 d protein expression of an adipocyte marker, fatty acid-binding protein 4, by 5-fold.

57 ey lipid binding protein adipocyte protein 2/fatty acid-binding protein 4.

58 ed a short-hairpin RNA (shRNA) for silencing fatty-acid-binding protein 4 (shFABP4), a key lipid chap

59 ptake and intracellular transport, including fatty-acid-binding proteins 4 and 5 (FABP4 and FABP5).

60 In addition, we report that fatty acid binding protein-4 (FABP4) messenger RNA is up

61 termediary metabolism and adipocyte biology (fatty acid binding protein-4 and growth differentiation

62 heparin-binding EGF-like growth factor, and fatty acid binding protein-4-had been previously describ

63 death in macrophages and prevents macrophage fatty acid-binding protein-4 (aP2) expression.

64 of lipid metabolism-related genes including fatty acid binding protein 5 (FABP5), fatty acid synthas

65 Downregulated genes included fatty acid binding protein 5, cyclin D1, and some signal

66 Fatty acid-binding protein 5 (FABP5) is expressed in lun

67 ar retinoic acid binding protein 2 (CRABP2), fatty acid-binding protein 5 (FABP5), retinoic acid rece

68 e, correlates with a marked up-regulation of fatty acid-binding protein 5 (FABP5).

69 designed an shRNA construct to mouse fabp5 (fatty acid-binding protein 5).

70 We identified fatty-acid binding protein 5 (FABP5) as an enhancer of t

71 Collagen type Ialpha, fatty-acid-binding-protein 5, nidogen-1, cartilage oligo

72 key pro-neural/neuronal factors, CSDE1 binds fatty acid binding protein 7 (FABP7) and vimentin (VIM)

73 its binding target by proteomic analysis as fatty acid binding protein 7 (FABP7), also known as brai

74 chemokine (C-X-C) motif ligand 12 (Cxcl12), fatty acid binding protein 7 (Fabp7), plasma membrane pr

75 heir lineage myelin protein zero (P0) and/or fatty acid binding protein 7 (Fabp7).

76 n and up-regulated the pro-migratory factors fatty acid-binding protein 7 (FABP7) and Ras homolog fam

77 ysis and identified that increased levels of fatty acid-binding protein 7 (FABP7) correlate with a lo

78 eration of mono-unsaturated fatty acids, and fatty acid-binding protein 7, a regulator of glioma stem

79 Fatty acid-binding protein-7 (FABP7) has been shown to b

80 The male germ cell-specific fatty acid-binding protein 9 (FABP9/PERF15) is the major

81 Here, we identify adipocyte-type fatty acid-binding protein (A-Fabp) and other members of

82 l abnormalities, plasma levels of intestinal fatty acid binding protein, a marker of enterocyte turno

83 Perfusate levels of fatty acid binding protein, a marker of tubular cell inj

84 Further, the folding of fatty acid binding protein, a predominantly beta-sheet p

85 In addition to acrylodan-labeled fatty acid binding protein, a probe that detects unbound

86 (e.g., major urinary proteins in the liver, fatty acid binding proteins, adipose differentiation-rel

87 hormone sensitive lipase (HSL) and adipocyte fatty acid-binding protein (AFABP) form a physical compl

88 Adipocyte fatty acid-binding protein (AFABP/aP2) facilitates the i

89 hormone-sensitive lipase (HSL) and adipocyte fatty acid-binding protein (AFABP/aP2) form a physical c

90 Adipocyte fatty acid-binding protein (AFABP/aP2) forms a physical

91 In addition to atherosclerosis, these fatty acid binding proteins also exert a dramatic impact

92 ctivated receptors, Toll-like receptors, and fatty acid-binding proteins, also act as links between n

93 glyceride lipase, plasma membrane-associated fatty acid binding protein and AMPKgamma3 subunit protei

94 helial barrier integrity markers (intestinal fatty acid binding protein and zonulin-1 levels), solubl

95 Plasma intestinal fatty acid-binding protein and citrulline concentrations

96 relation between plasma levels of intestinal fatty acid-binding protein and citrulline.

97 diminished the expression of intestinal-type fatty acid-binding protein and lactate dehydrogenase (34

98 ion defects such as expression of intestinal fatty acid-binding protein and pancreatic trypsin.

99 The link between intestinal fatty acid-binding protein and plasma citrulline concent

100 es a fatty acid transporter), Fabp2 (encodes fatty acid binding protein), and Hadh (encodes hydroxyac

101 se-associated lipocalin, IL-18, KIM-1, liver fatty acid binding protein, and albumin associated indep

102 -18, kidney injury molecule-1 (KIM-1), liver fatty acid binding protein, and albumin.

103 a levels of soluble CD14 (sCD14), intestinal fatty acid binding protein, and interleukin-6 by enzyme-

104 cyte injury, including troponins, heart-type fatty acid binding protein, and myosin light chain-1, ma

105 embrane and internal sites, by intracellular fatty acid binding proteins, and by enzymes in synthetic

106 g adipocyte differentiation-related protein, fatty acid-binding protein, and cathepsin E.

107 ylglycerol acyltransferase activities, CD36, fatty acid-binding protein, and fatty acid transport pro

108 , C/EBPalpha, C/EBPdelta, SREBP-1, epidermal fatty acid-binding protein, and SCD.

109 l marker genes such as tranferrin, epidermal fatty acid-binding protein, androgen-binding protein, an

110 The fatty acid binding proteins aP2 (fatty acid binding prot

111 The fatty acid-binding protein aP2 is a cytoplasmic lipid ch

112 measuring their ability to induce adipocyte fatty acid-binding protein (aP2) mRNA expression.

113 olved in lipid metabolism, such as adipocyte fatty acid-binding protein (aP2), lipoprotein lipase (LP

114 ated more lipid and expressed more adipocyte fatty acid-binding protein (aP2), peroxisome proliferato

115 -acid binding protein (L-FABP) and adipocyte fatty acid-binding protein (aP2), two established PPARga

116 e in adipose tissue, driven by the adipocyte fatty acid-binding protein (aP2, also known as aFABP) pr

117 Adipocyte/macrophage fatty acid binding proteins, aP2 and mal1, act at the in

118 Adipocyte fatty-acid-binding protein, aP2 (FABP4) is expressed in

119 Fatty acid binding proteins are clearly important in reg

120 These fatty acid binding proteins are involved in the formatio

121 Fatty acid-binding proteins are cytosolic fatty acid cha

122 il gelatinase-associated lipocalin and liver fatty acid-binding protein associations with both defini

123 chain protein, low Abeta1-42, and high heart fatty acid-binding protein at baseline were related to f

124 reviously shown that regulation of the brain fatty acid-binding protein (B-FABP; FABP7) and glial fib

125 The expression of cutaneous fatty acid-binding protein (C-FABP) in prostate tissues

126 he adipocyte marker genes adipsin, adipocyte fatty acid-binding protein, C/EBPalpha, PPARgamma, and l

127 , osteopontin (OPN), sorbitol dehydrogenase, fatty acid binding protein, cadherin-5, macrophage colon

128 a and fibroblast growth factor 4, heart-type fatty acid binding protein, calcitonin, and tumor necros

129 l markers, the intestinal markers intestinal fatty acid binding protein, CDX1 and CDX2 were rarely ex

130 )-deficient (CFTR knockout, Cftr(tm1Unc-)TgN(fatty acid-binding protein)CFTR) and mutant (DeltaF508)

131 paxillin suggests that S100A7 and epidermal fatty acid binding protein colocalize in focal adhesion-

132 e studies indicate that S100A7 and epidermal fatty acid binding protein colocalize in the cytoplasm i

133 ulline</=12.2 mumol/L, and plasma intestinal fatty acid-binding protein concentration>/=355 pg/mL wer

134 This review will highlight recent studies on fatty acid binding protein-deficient models and several

135 an-shaped body, increasing the expression of Fatty acid binding protein (dFabp), or by administering

136 Mechanistically, epidermal fatty acid binding protein (E-FABP) was significantly up

137 Epidermal fatty acid-binding protein, E-FABP, a lipid chaperone, h

138 Intestinal fatty acid-binding protein elevation at admission to the

139 R(2) = 0.25) expressions and with changes in fatty acid binding protein expression (R(2) = 0.33).

140 auged by significant reduction of intestinal fatty acid-binding protein expression.

141 ticipants had higher levels of CCL5, CXCL10, fatty acid binding protein (FABP) 2, fas ligand (FASLG),

142 approaches, and the levels of CSF heart-type fatty acid binding protein (FABP) and 12 other correlate

143 we reported that a native Fasciola hepatica fatty acid binding protein (FABP) termed Fh12 is a power

144 The adipocyte fatty acid-binding protein (FABP) aP2 is expressed by ad

145 e report that mite group 13 allergens of the fatty acid-binding protein (FABP) family are sensed by a

146 ng protein (A-Fabp) and other members of the fatty acid-binding protein (Fabp) family as interaction

147 ein family and Z found to be a member of the fatty acid-binding protein (FABP) family.

148 sis is mediated, in part, via interaction of fatty acid-binding protein (FABP) with hormone-sensitive

149 adipocytes expressed adiponectin, perilipin, fatty acid-binding protein (FABP), leptin, C/EBPalpha, a

150 essing progastrin (PG) in intestinal mucosa (fatty acid-binding protein (Fabp)-PG mice) are at an inc

151 Fatty acid-binding proteins (FABP) are known central reg

152 ems have demonstrated a role for cytoplasmic fatty acid-binding proteins (FABP) in lipid metabolism,

153 The enterocyte expresses two fatty acid-binding proteins (FABP), intestinal FABP (IFA

154 Fatty-acid binding proteins (FABP) and myeloperoxidases

155 The fatty acid binding proteins aP2 (fatty acid binding protein [FABP]-4) and mal1 (FABP5) ar

156 ding those for the anticipated targets liver fatty acid binding protein (Fabp1) and lactase-phlorizin

157 Serum liver-type fatty acid binding protein (FABP1) early (day 1) or late

158 test the central hypothesis that liver-type fatty acid binding protein (FABP1) mediates phytocannabi

159 Here, we demonstrate that the heart-type fatty acid-binding protein, FABP3, is essential for cold

160 Recent studies demonstrate that adipose fatty acid binding protein (FABP4) promotes obesity-asso

161 Targeted deletion of the murine fatty acid binding protein (FABP4/aP2) uncouples obesity

162 demonstrated that deletion of the adipocyte fatty acid-binding protein (FABP4/aP2) uncouples obesity

163 pite the abundant expression of adipose-type fatty acid-binding protein, FABP4 (also known as aP2).

164 onectin, perilipin, and the adipose-specific fatty acid-binding protein, FABP4/aP2.

165 A-binding proteins CRABP1 and CRABP2 and the fatty acid-binding protein FABP5 are dynamically express

166 We show further that the fatty acid-binding protein FABP5 controls both of these

167 The fatty acid-binding protein FABP5 shuttles ligands from t

168 The astrocyte brain fatty acid binding protein (Fabp7) has previously been s

169 In mammals, serum albumin, fatty acid binding proteins (FABPs) and organic anion tr

170 Three fatty acid binding proteins (FABPs) known to be expresse

171 Fatty acid binding proteins (FABPs) serve as intracellul

172 netic analysis of avian and other vertebrate fatty acid binding proteins (FABPs) supported the hypoth

173 Fatty acid binding proteins (FABPs), in particular FABP5

174 Fatty acid-binding proteins (FABPs) act as intracellular

175 tricted coexpression of adipocyte/macrophage fatty acid-binding proteins (FABPs) aP2 (FABP4) and mal1

176 Fatty acid-binding proteins (FABPs) are a widely express

177 Fatty acid-binding proteins (FABPs) are abundant intrace

178 The intracellular fatty acid-binding proteins (FABPs) are abundantly expre

179 Fatty acid-binding proteins (FABPs) are cytosolic fatty

180 Fatty acid-binding proteins (FABPs) are intracellular pr

181 Recently, we identified fatty acid-binding proteins (FABPs) as intracellular NAE

182 cular homeostasis and are bound by cytosolic fatty acid-binding proteins (FABPs) with K(d) values of

183 llular lipid-binding proteins, including the fatty acid-binding proteins (FABPs), can chaperone ligan

184 fatty acid kinase (FakA), whereas bound by a fatty acid-binding protein (FakB).

185 n P2 is a peripheral membrane protein of the fatty acid-binding protein family that functions in the

186 inity drug-like compound and a member of the fatty acid-binding protein family.

187 enesis, such as lipid droplet morphology and fatty acid binding protein (FAPB)-4 expression, were not

188 In vitro, these proteins are fatty-acid-binding proteins (FAPs).

189 ticle that a single i.p. injection of 15 mug fatty acid binding protein from Fasciola hepatica (Fh12)

190 creation of pharmacological agents to modify fatty acid binding protein function will provide tissue

191 ed a TE-gene chimeric transcript involving a fatty acid-binding protein gene (LTR2-FABP7), normally e

192 Heart-type fatty acid binding protein (H-FABP) is a cytosolic prote

193 Heart fatty acid binding protein (H-FABP) is expressed in neur

194 n basic protein (MBP), S100B, and heart-type fatty acid binding protein (H-FABP) were measured in CSF

195 We addressed this issue using heart fatty acid-binding protein (H-FABP) gene-ablated mice.

196 e if a high-performance assay for heart-type fatty acid-binding protein (H-FABP) has a role in predic

197 librium unfolding behavior of the intestinal fatty acid-binding protein has been investigated by (19)

198 Heart type fatty acid binding protein (HFABP) as an early marker of

199 NTA, to screen PFASs binding to human liver fatty acid binding protein (hL-FABP).

200 Intestinal fatty acid binding protein (I-FABP) and lipopolysacchari

201 Intestinal fatty acid binding protein (I-FABP) arteriovenous (V-A)

202 The human intestinal fatty acid binding protein (I-FABP) belongs to a family

203 s of the enterocyte damage marker Intestinal fatty acid binding protein (I-FABP) than IR.

204 t microbial translocation marker (intestinal fatty acid binding protein (I-FABP)) were measured in 25

205 We measured plasma intestinal fatty acid binding protein (I-FABP), soluble CD14 (sCD14

206 Analogous to that in the intestinal fatty acid binding protein (I-FABP), we hypothesize that

207 renine/tryptophan (KT) ratio, and intestinal fatty acid binding protein (I-FABP).

208 (LBP), soluble CD14 (sCD14), and intestinal fatty acid binding protein (I-FABP).

209 ed apoptosis-inducing ligand, and intestinal fatty acid-binding protein (I-FABP) than survivors.

210 e (LPS), endotoxin core antibody, intestinal fatty acid-binding protein (I-FABP), soluble CD14 (sCD14

211 determinants of plasma levels of intestinal fatty acid-binding protein (I-FABP/FABP2), a marker of g

212 ctor [TNF]), enterocyte turnover (intestinal fatty acid binding protein [I-FABP]), lipopolysaccharide

213 s problem has been simplified for intestinal fatty acid binding protein (IFABP) by incorporating fluo

214 Rat intestinal fatty acid binding protein (IFABP) displays an intermedi

215 The intestinal fatty acid binding protein (IFABP) is a small (15 kDa) p

216 The intestinal fatty acid binding protein (IFABP) is composed of two be

217 The rat intestinal fatty acid binding protein (IFABP) primarily comprises t

218 ctional all-beta sheet variant of intestinal fatty acid binding protein (IFABP) that was generated by

219 of 4-(19)F-phenylalanine into the intestinal fatty acid binding protein (IFABP), a protein composed o

220 alpha-lactalbumin, cytochrome c, intestinal fatty acid binding protein (IFABP), and myoglobin.

221 ier damage as indicated by plasma intestinal fatty acid binding protein (IFABP), T-cell activation, a

222 (pCFTR) cDNA under control of the intestinal fatty acid-binding protein (iFABP) promoter would allevi

223 igration inhibitory factor (MIF), intestinal fatty acid-binding protein (IFABP), and proinflammatory

224 eosinophil granule proteins, and intestinal fatty acid-binding protein (IFABP).

225 valuated the usefulness of plasma intestinal fatty-acid binding protein (IFABP) levels in the early i

226 rkers (LPS, soluble CD14 [sCD14], intestinal fatty acid-binding protein [iFABP], and endotoxin core I

227 Intestinal fatty acid-binding protein, IL6, and soluble CD14 were h

228 identify factors associated with intestinal fatty acid-binding protein in critically ill patients.

229 neral protein interaction domain utilized by fatty acid-binding proteins in regulatory control of lip

230 had higher plasma levels of LPS, intestinal fatty acid binding protein (indicating enterocyte death)

231 Fatty acid binding proteins integrate metabolic and immu

232 , we show that the test protein, human liver fatty acid binding protein, interacts reversibly and per

233 Epidermal fatty acid binding protein is also overexpressed in psor

234 Intestinal fatty acid-binding protein is a marker of enterocyte dam

235 Heart-type fatty acid-binding protein is released into the circulat

236 ry molecule-1 (KIM-1), IL-18, and liver-type fatty acid binding protein (L-FABP) from 1304 deceased d

237 Liver fatty acid binding protein (L-FABP) has been proposed to

238 Although liver fatty acid binding protein (L-FABP) is known to bind not

239 Liver fatty acid binding protein (L-Fabp) modulates lipid traf

240 ry molecule-1 (KIM-1), IL-18, and liver-type fatty acid binding protein (L-FABP) were measured in spo

241 Liver fatty acid binding protein (L-FABP), a cytosolic protein

242 kidney injury molecule-1 (KIM-1), liver-type fatty acid binding protein (L-FABP), and albumin differe

243 kidney injury molecule-1 (KIM-1), liver-type fatty acid binding protein (L-FABP), and interleukin (IL

244 ith proteins--including serum albumin, liver fatty acid binding proteins (L-FABP), and organic anion

245 on of the two lipid transfer proteins, liver fatty acid-binding protein (L-FABP) and MTP, which coope

246 was addressed in cells expressing liver-type fatty acid-binding protein (L-FABP) by real time multiph

247 Whereas the role of liver fatty acid-binding protein (L-FABP) in the uptake, trans

248 Liver fatty acid-binding protein (L-Fabp) is an abundant cytos

249 Although liver fatty acid-binding protein (L-FABP) is an important bind

250 Liver fatty acid-binding protein (L-Fabp) regulates murine hep

251 Here we show that liver fatty acid-binding protein (L-Fabp), an abundant cytosol

252 luorescence colocalization showed that liver fatty acid-binding protein (L-FABP; binds LCFA-CoA as we

253 he bands contained both liver and intestinal fatty acid-binding proteins (L- and I-FABP) as well as f

254 gonucleotide and induced expression of liver fatty-acid binding protein (L-FABP) and adipocyte fatty

255 lipocalin [NGAL], interleukin [IL]-18, liver fatty acid-binding protein [L-FABP], and kidney injury m

256 pathway is mediated by a lysosome-associated fatty acid binding protein LBP-8 in Caenorhabditis elega

257 A7 expression appears to stabilize epidermal fatty acid binding protein level, and vice versa.

258 Liver fatty acid-binding protein (LFABP) binds long-chain fatt

259 Liver fatty acid-binding protein (LFABP) is a 14 kDa cytosolic

260 Rat liver fatty acid-binding protein (LFABP) is distinctive among

261 patic cathepsin B and lower amounts of liver fatty acid-binding protein (LFABP) than their wildtype l

262 Liver fatty acid-binding protein (LFABP; FABP1) is expressed b

263 me to ART initiation, viral load, intestinal fatty acid-binding protein, LPS, and soluble LPS recepto

264 A second fatty acid-binding protein, mal1, also is expressed in a

265 binding protein-deficient models and several fatty acid binding protein-mediated pathways specificall

266 ree test cases: one complex involving muscle fatty acid-binding protein (mFABP) and two complexes inv

267 royl-CoA desaturase-1 (SCD-1), and epidermal fatty acid-binding protein more than rat serum alone.

268 glycogen phosphorylase), transport proteins (fatty acid-binding protein, myoglobin and somatic cytoch

269 otein (LBP), beta-D-glucan (BDG), intestinal fatty-acid binding protein, oxidized low-density lipopro

270 ncluded glutathione S-transferase (P<0.001), fatty acid binding protein (P<0.001), and alanine aminop

271 These included fatty acid binding protein, phospholipid binding protein

272 Fatty acid binding proteins play an important role in th

273 Heart-type fatty acid-binding protein predicts long-term mortality

274 ed CFTR(-/-) mice bearing a transgene with a fatty acid binding protein promoter driving expression o

275 Nucleotides -596 to +21 of the rat liver fatty acid-binding protein promoter were used to direct

276 s glutathione S-transferase, LDH, heart-type fatty acid binding protein, redox-active iron, IL-18, an

277 ase, lactate dehydrogenase (LDH), heart-type fatty acid binding protein, redox-active iron, interleuk

278 Furthermore, expression of the liver fatty acid binding protein reduced the availability of b

279 patocyte and stellate cell deletion of liver fatty acid binding protein reveal distinct roles in fibr

280 site-specific mutants of the rat intestinal fatty acid binding protein (rI-FABP) with acrylodan.

281 mics around a beta-barrel protein, rat liver fatty acid-binding protein (rLFABP), to reveal the effec

282 mucosal dysfunction markers intestinal-type fatty acid-binding protein, soluble suppression of tumor

283 s a marked delay in expression of intestinal fatty acid binding protein, suggesting a role for PTK6 i

284 The FakBs are fatty acid binding proteins that exchange bound fatty ac

285 g cells with ADIFAB, a fluorescently labeled fatty acid-binding protein that is used to measure unbou

286 tochondrial biogenesis and function, to be a fatty-acid-binding protein that preferentially binds LD-

287 epatic lipase, endothelial lipase, the liver fatty acid-binding protein, the beta3-adrenergic recepto

288 wever, with BSA present to mimic cytoplasmic fatty acid-binding proteins, the mitochondrial populatio

289 ar RA binding protein type II (CRABP-II) and fatty acid binding protein type 5 in adipocytes and skel

290 kidney injury molecule-1, urinary liver-type fatty acid binding protein, urinary interleukin-18, and

291 re, a gap-closed variant of human intestinal fatty acid binding protein was generated by mutagenesis,

292 (+/+) cells, and hepatic expression of liver fatty acid binding protein was lower in p110-alpha(-/-)

293 The GI mucosal intestinal fatty acid-binding protein was decreased after transplan

294 FA, ADIFAB (acrylodan-labeled rat intestinal fatty acid-binding protein), was microinjected into isol

295 Blood citrulline and intestinal fatty acid binding protein were determined as biomarkers

296 Serum levels of troponin T and heart-type fatty acid binding protein were increased (P < 0.05) aft

297 osphorylated tau, alpha-synuclein, and heart fatty acid-binding protein were quantified by 2 blinded

298 chain protein, low Abeta1-42, and high heart fatty acid-binding protein were related to future PDD, p

299 ney injury molecule-1, IL-18, and liver-type fatty acid binding protein with graft failure (GF) and d

300 like albumin in plasma and interstitium and Fatty Acid-Binding Proteins within endothelium and cardi